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Abstract
This chapter discusses the management of dyslipidemia in special patient 
populations: the elderly, woman and pregnancy, renal disease, human immunodefi-
ciency virus (HIV), and different racial/ethnic groups. In the elderly, dyslipidemia 
is often underdiagnosed and undertreated. Consideration for potential athero-
sclerotic risk-reduction benefits, risk of adverse effects, drug-drug interactions, 
and patient preferences should precede the initiation of statin therapy. Data on 
pregnant women are lacking and need future research. Dyslipidemia and its effects 
on the cardiovascular system in chronic kidney disease (CKD), end-stage renal 
disease (ESRD), and HIV are dynamic and multimodal. These conditions are states 
of chronic inflammation, where it is difficult to associate quantities of cholesterol 
types with outcomes. Among all racial groups, Asian Indians, Filipinos, and 
Hispanics are at a higher risk for dyslipidemia. Genetic differences in statin metabo-
lism may explain this racial/ethnic difference.
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1. Introduction
Dyslipidemia, defined as high levels of low-density lipoprotein cholesterol (LDL-C) 
(≥130 mg/dl), total cholesterol (≥200 mg/dl), and triglycerides (TG) (≥150 mg/dl), 
or low levels of high-density lipoprotein cholesterol (HDL-C) [<40 (men) and < 50 
(women) mg/dl], is a major risk factor for cardiovascular disease (CVD). Significant 
heterogeneity in patterns of dyslipidemia exists in these special populations. There is 
confusion among health-care providers regarding selection and implementation of 
appropriate guidelines, particularly for special patient populations. Patients in special 
populations may not clearly fall into one of the four statin-benefit groups identified by 
the ACC/AHA cholesterol guidelines [1].
In this chapter, we review the evidence in patterns of dyslipidemia and manage-
ment in the elderly, women and pregnancy, CKD, ESRD, HIV, and different racial/
ethnic groups.
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2. Dyslipidemia in the elderly
2.1 Epidemiology
According to census projections, the population age 65 and older is expected 
to double between 2012 and 2060, from 43.1 to 92.0 million [2]. CVD is the main 
cause of mortality in this age group. Lipid-lowering pharmacological intervention 
is one of the most successful cardiovascular preventative interventions. Concerns 
about its safety and efficacy in this age group have led different countries to adopt 
different strategies concerning the use of lipid-lowering drugs in the elderly [3]. 
In US population as reported in the National Health and Nutrition Examination 
Survey (NHANES) publications, across all age groups, triglyceride levels increase 
with age and reach a peak in men aged 50–59 years and in women aged 60–69 years. 
Apolipoprotein B (Apo B) and small dense LDLc also increase with age, while 
HDL-c does not seem to vary with age [4].
2.2 Management
Lifestyle modification including adhering to a heart healthy diet, regular exer-
cise, avoidance of tobacco products, and maintenance of a healthy weight remains a 
critical component of ASCVD risk reduction.
2.2.1 Secondary prevention statin trials in elderly
In general, the elderly are usually underrepresented in published clinical tri-
als. The only large randomized statin trials that focused on older patients are the 
Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) and the Study 
Assessing Goals in the Elderly (SAGE) trial.
PROSPER is a randomized controlled trial in which 5804 patients aged 
70–82 years with a history of, or risk factors for, vascular disease were ran-
domized to receive pravastatin (40 mg/day; n = 2891) or placebo (n = 2913). 
Follow-up was 3.2 years. Pravastatin was found to reduce the incidence of 
coronary death, nonfatal myocardial infarction, and fatal or nonfatal stroke. 
Suggesting pravastatin may be utilized to manage dyslipidemia in the elderly 
and be prescribed to [5]. Later, the Study Assessing Goals in the Elderly (SAGE) 
compared the effect of intensive (atorvastatin 80 mg/day) with moderate 
(pravastatin 40 mg/day) cholesterol lowering with statins in a cohort of 893 
patients, 65–85 years of age with coronary artery disease (CAD), and follow-up 
for 12 months. Atorvastatin-treated patients experienced greater LDL-C reduc-
tions than did pravastatin-treated patients, a trend toward fewer major acute 
cardiovascular events and a significantly greater reduction (77%) in all-cause 
death [6].
British Heart Foundation Heart Protection Study evaluated the role of simv-
astatin 40 mg/day versus placebo in 20,536 patients with coronary atherosclerosis 
and diabetics with coronary heart disease (CHD) risk equivalence. About 28% 
of randomized patients were ≥70 years of age. Among the 1263 individuals with 
75–80 years of age at study entry, the rate of major coronary events in the simvastatin 
group was significantly lower than placebo group [7]. The long-term intervention 
with pravastatin in ischemic disease (LIPID) trial randomized patients with prior 
myocardial infarction or unstable angina to receive pravastatin 40 mg/day versus 
placebo, of which 39% (3514) were of age 65–75 years. Here, pravastatin reduced 
the risk for all CVD events, and similar adverse effects were observed in older and 
younger patients [8].
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Other major secondary prevention trials, which included large numbers of 
elderly patients, are cholesterol and recurrent events (CARE) and Scandinavian 
simvastatin survival study (4S). In subgroup analyses of both studies, the absolute 
benefit of treatment was significantly greater in older patients as compared to 
younger patients for cardiovascular events [9, 10]. The 2013 ACC/AHA guidelines 
on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk 
in adults recommended high-intensity statin therapy should be initiated or con-
tinued as first-line therapy in women and men ≤75 years of age who have clinical 
atherosclerotic cardiovascular disease (ASCVD), unless contraindicated. A larger 
amount of data supports the use of moderate-intensity statin therapy for secondary 
prevention in individuals with clinical ASCVD who are >75 years of age. However, 
the limited information available did not clearly support initiation of high-intensity 
statin therapy for secondary prevention in individuals >75 years of age [1]. Statin 
therapy to higher risk elderly patients is appropriate. In individuals with clinical 
ASCVD >75 years of age, practitioners should evaluate the potential for ASCVD 
risk-reduction benefits, adverse effects, drug-drug interactions and consider 
patient preferences when initiating a moderate- or high-intensity statin. It is rea-
sonable to continue statin therapy in those who are tolerating it [1, 11]. Physicians 
treating the elderly must also consider the functional age of the patient and the 
impact of long-term drug therapy on safety and quality of life. Caution is recom-
mended when statins are used in frail elderly patients, who may be more susceptible 
to drug-related myopathy and other side effects [12].
2.2.2 Primary prevention and statin trials
The Anglo-Scandinavian Cardiac Outcomes trial randomized 19,342 hyperten-
sive patients (aged 40–79 years with at least three other cardiovascular risk factors) 
to be assigned to atorvastatin 10 mg or placebo. Nonfatal myocardial infarction 
and fatal cardiovascular disease were significantly lower in the statin group [13]. 
In a post hoc analysis, efficacy and safety of atorvastatin in 1129 patients aged 
65–75 years at randomization was compared with 1709 younger patients in the 
Collaborative Atorvastatin Diabetes Study (CARDS). Primary end point of time to 
first occurrence of acute coronary heart disease events, coronary revascularizations, 
or stroke was similar in both groups. The overall safety profile of atorvastatin was 
similar between age groups [14]. Justification for the Use of statins in Prevention: 
An Intervention Trial Evaluating Rosuvastatin (JUPITER) is a randomized, double-
blind, placebo-controlled trial with 17,802 participants of which 5695 were 70 years 
or older with LDL-C levels <130 mg/dl and high-sensitivity C-reactive protein levels 
of 2.0 mg/L or more without cardiovascular disease and were randomly assigned 
in a 1:1 ratio to receive 20 mg of rosuvastatin daily or placebo. In secondary analysis 
of this trial, no significant heterogeneity was found in treatment effects by age, 
absolute reductions in event rates associated with rosuvastatin were greater in 
elderly. The relative rate of any serious adverse event among older patients in the 
rosuvastatin versus placebo group was 1.05 (CI, 0.93–1.17) [15, 16].
As per 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce 
atherosclerotic cardiovascular risk in adults; four statin benefit groups are individu-
als with ASCVD, individuals with primary elevations of LDL-C ≥ 190 mg/day,  
individuals 40–75 years of age with diabetes and LDL-C 70 to 189 mg/dl without 
clinical ASCVD, and individuals without clinical ASCVD or diabetes who are 
40–75 years of age and have LDL-C 70–189 mg/dl and an estimated 10-year ASCVD 
risk of ≥7.5%. This requires a clinician-patient discussion. Few data are available to 
indicate an ASCVD event reduction benefit in primary prevention among indi-
viduals >75 years of age who do not have clinical ASCVD. Therefore, initiation of 
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statins for primary prevention of ASCVD in individuals >75 years of age requires 
consideration of additional factors, including increasing comorbidities, safety con-
siderations, and priorities of care. The Pooled Cohort Equations can also provide 
information on expected 10-year ASCVD risk for those 76–79 years of age that may 
inform the treatment decision. A discussion of the potential ASCVD risk-reduction 
benefits, risk of adverse effects, drug-drug interactions, and consideration of 
patient preferences should precede the initiation of statin therapy for primary 
prevention in older individuals [1].
2.2.3 Statin and side effects
In the PROSPER study, no rhabdomyolysis or serum CK concentration > 10 
times the upper limit of normal was reported. There was no statistically significant 
difference in the incidence of reported myalgia between the pravastatin and placebo 
groups (1.2 and 1.1%, respectively). In the SAGE study, incidence of myalgia was 
also not different between the atorvastatin and pravastatin treatment groups (3.1% 
versus 2.7%) with only one individual found to have CK level > 10 times the upper 
limit of normal in the pravastatin treatment group but none in the atorvastatin 
group [5, 6]. In a retrospective study, Graham et al. reported rhabdomyolysis risk 
was similar and low for monotherapy with atorvastatin, pravastatin, and simvas-
tatin. Combined statin-fibrate use was associated with increased risk, especially in 
older patients with diabetes mellitus [17].
All of the available statins, with the exception of pravastatin and rosuvastatin, 
are metabolized by the cytochrome P450 (CYP) system. Serum concentrations of 
these statins can potentially be increased when other medications competing for the 
CYP system or CYP isoenzyme inhibitors are prescribed and can lead to increased 
risk of myositis and rhabdomyolysis. There is an age-related decrease in glomerular 
filtration rate, decrease in hepatic blood flow, decrease in drug clearance, and 
increased expression of P-glycoproteins resulting in alterations in the rate of drug 
transport across cellular membranes [18–20].
2.3 Other medications
2.3.1 Ezetimibe
Improved Reduction of Outcomes: Vytorin Efficacy International Trial 
(IMPROVE-IT) evaluated the effect of ezetimibe combined with simvastatin, as 
compared to simvastatin alone in 18,144 patients with acute coronary syndrome. 
Subgroup analysis showed a benefit of ezetimibe in the 7971 patients’ over 65 years 
and 2798 patients’ over 75 years of age [21].
2.3.2 Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
The first large cardiovascular outcome study using PCSK9 inhibitor therapy 
(FOURIER) was a randomized, double-blind placebo-controlled trial of 27,564 
subjects with 12,254 patients over the age 65 years with ASCVD and LDL-C levels 
≥70 mg/dl while on maximally tolerated statin therapy, randomly assigned to 
receive evolocumab or placebo. In these patients, there was a significant decrease 
in composite outcome of cardiovascular death, myocardial infarction (MI), stroke, 
hospitalization for unstable angina, or coronary revascularization. However, cost is 
prohibitive for generalized use [22].
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2.3.3. Fibrates
No data are available for fibrates in patients over 75 years of age. World Health 
Organization Clofibrate Study, Helsinki Heart Study (HHS), Bezafibrate Infarction 
Prevention (BIP), and Veterans Affairs Program High-Density Lipoprotein 
Cholesterol Intervention Trial (VA-HIT) showed reduction in the risk of myocardial 
infraction. Fenofibrate is considered the preferred agent, due to once-daily dosing 
and a favorable adverse reactions profile. Caution is needed in elderly patients with 
reduced renal function [23–26].
In conclusion, cardiovascular prevention clinical trial evidence for the patients over 
age 75 years is very limited. Management of dyslipidemia in the elderly requires consid-
eration of comorbidities, safety considerations, polypharmacy, and priorities of care.
3. Dyslipidemia in women
3.1 Gender and cardiovascular risk
CVD is a major cause of death in women. While the risk of CVD in men 
increases after age 40 years, risk develops 7–10 years later in women. Incidence of 
CAD in premenopausal women is 3–4 times lower than in men [27, 28]. After meno-
pause due to loss of vasodilating property of estrogen and increased sympathetic 
activity, the risk of CAD is increased and is similar to men [29–31]. Risk factors 
unique to women are use of oral contraceptives, menopause, hormone replacement 
therapy, gestational hypertension, and diabetes. Obesity and metabolic syndrome 
are also more prevalent in women [32].
Plasma cholesterol levels and LDL-C levels are similar in both sexes during the 
infancy and adolescence. LDL levels increase progressively in both men and women 
after the age of 20, but more rapidly in men. Size of the LDL particles reduces as men 
age, while it remains stable in women until menopause then becomes smaller [33].
3.2 Management of dyslipidemia
In 1999, American heart association (AHA) developed the first women-specific 
clinical report regarding recommendations for CVD prevention [34]. In the 2011 
AHA update, effectiveness-based guidelines for the prevention of CVD in women 
recommended lifestyle approaches for LDL-C < 100 mg/dl, HDL-C > 50 mg/dl, 
triglycerides <150 mg/dl, and non-HDL-C (total cholesterol minus HDL) <130 mg/dl  
(class I recommendation; level of evidence B). LDL-C-lowering drug therapy 
with lifestyle therapy in women with coronary heart disease (CHD) to achieve an 
LDL-C < 100 mg/dl (class I; level of evidence A) and is also indicated in women 
with other atherosclerotic CHD or diabetes mellitus or 10-year absolute risk 20% 
(class I; level of evidence B). A reduction to <70 mg/dl is reasonable in very-high-
risk women like those with recent acute coronary syndrome (ACS) or multiple 
cardiovascular risk factors with CHD and may require an LDL-lowering drug 
combination (class IIa; level of evidence B). In women >60 years of age and with an 
estimated CHD risk >10%, statins could be considered if hsCRP is >2 mg/dl after 
lifestyle modification and no acute inflammatory process is present (class IIb; level 
of evidence B). Niacin or fibrate therapy can be useful when HDL-C is low (<50 mg/dl)  
or non-HDL-C is elevated (>130 mg/dl) in high-risk women after LDL-C goal is 
reached (class IIb; level of evidence B) [35].
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In 2013 ACC/AHA guidelines added, treatment decisions for women should 
be based on the level of ASCVD risk. Statin treatment based on estimated 10-year 
ASCVD risk avoids the overtreatment of lower risk groups, such as younger, non-
Hispanic white women who, despite moderate elevations in LDL-C, are typically 
not at significantly increased risk for ASCVD in the absence of other substantial 
risk factors [1]. The European Atherosclerosis Society (ESC/EAS) recommends that 
assessment of CV risk should be gender specific and recommended statin therapy 
be initiated as primary and secondary prevention for women at high risk [36].
3.3 Women in hyperlipidemia clinical trials
Women have been underrepresented in many primary and secondary preven-
tion trials. In major primary prevention trials, the number of women varied from 15 
to 49%. In AFCAPS (15%), HPS (30%), ALLHAT-LLT (49%), and in ASCOT-LLA 
trial (19%) were women [37, 38]. In a prospective, randomized, open-labeled, 
blinded Japanese primary prevention trial of patients with hypercholesterolemia, 
5547 (68%) were women randomly assigned to diet alone or diet with pravastatin 
daily. Treatment with a low dose of pravastatin reduced the risk of CHD but sub-
group analysis of CHD risk in women was not statistically significant [39]. JUPITER 
trial participants included 6801 women ≥60 years of age and 11,001 men ≥50 years 
of age with high-sensitivity C-reactive protein ≥2 mg/L and LDL-C < 130 mg/dl,  
randomized to rosuvastatin versus placebo. JUPITER demonstrated that for pri-
mary prevention, rosuvastatin reduced CVD events in women with a relative risk 
reduction similar to that in men, a finding supported by meta-analysis of primary 
prevention statin trials [40].
In major secondary prevention trials, 4S included 827 (19% woman), CARE 
576 (14%), LIPID 1516 (17%), TNT 1902 (19%), and SEARCH trial included 2052 
(17%) women [41–44]. Cholesterol lowering with simvastatin produced similar 
reductions in relative risk for major coronary events in women compared with men. 
There were too few female deaths to assess the effects on mortality in women [41]. 
A meta-analysis of 13 large trials for a total of 11,435 women in primary prevention 
and 8272 in secondary prevention concluded that lipid lowering does not affect 
CHD mortality in women for primary prevention, but it is effective for secondary 
prevention [27].
3.4 Gender differences in statin use
Women are more likely to have poor lipid control. There have been conflict-
ing results regarding gender differences in benefit of statins in women with 
CVD. However, in a meta-analysis performed on data from 22 trials of statin therapy 
versus control (n = 134,537) and five trials of more intensive versus less intensive 
statin therapy, 27% of 174,149 randomized participants were women. In men and 
women at an equivalent risk of cardiovascular disease, statin therapy was equally 
effective for the prevention of major vascular events. Kostis et al. performed a meta-
analysis consisting of 18 randomized clinical trials of statins with gender-specific 
outcomes and found statin therapy was associated with significant decreases in 
cardiovascular events and in all-cause mortality in women and men [45].
There is a gender-specific impact of transporter polymorphisms on statin phar-
macokinetics. Estrogen-induced water and sodium retention, increased volume for 
lipophilic drugs, higher protein-binding globulins, higher CYP3A4 activity, lower 
body mass index, and lower renal clearance in women may affect absorption of 
different statins. Women seem to be at greater risk of statin-induced rhabdomyoly-
sis. In a US case-control study of 252,460 users of lipid-lowering therapy, there was 
7Dyslipidemia in Special Populations, the Elderly, Women, HIV, Chronic Kidney Disease…
DOI: http://dx.doi.org/10.5772/intechopen.82831
trend for increased risk of rhabdomyolysis [46]. In the JUPITER study, the occur-
rence of serious adverse events was similar in both men and women [40].
3.5 Pregnancy
3.5.1 Normal changes in pregnancy
Metabolic adaptations during pregnancy are essential to meet the physiological 
demands of pregnancy as well as development of the fetus. An increase in insulin 
resistance results in increases in maternal glucose and free fatty acid concentra-
tions, allowing for greater substrate availability for fetal growth. Production of 
progesterone leads to lipogenesis, lipids are transported across the placenta and 
metabolized; this signifies the essential role of lipids to normal fetal development 
[47, 48]. Within 6 weeks of gestation, lipid levels drop slightly followed by rise in 
both total cholesterol and marked increase in triglycerides (TG). HDL-C levels and 
apolipoprotein A-I levels also increase during normal gestation, with peak levels 
during the second trimester. As TG levels rise, there is a decrease in low-density 
lipoprotein (LDL) size with an increased proportion of atherogenic small-dense 
LDL. Both cholesterol and triglyceride concentrations decrease significantly 
within 24 h of delivery. However, while TG levels continued to decrease rapidly 
returning to nonpregnant levels during the puerperium, LDL-C remained elevated 
for at least 6–7 weeks postpartum [49, 50]. During pregnancy, lipoprotein Lp(a) 
levels increase with gestational age and fall to prepregnancy levels within 6 months 
postpartum [51, 52].
3.5.2 Lipids and complications in pregnancy
Preeclamptic women exhibit higher mean serum TG levels, elevated LDL-C 
fractions, increased levels of Lp(a), and lower HDL cholesterol levels com-
pared with healthy pregnant women [49]. Amsterdam Born Children and Their 
Development (ABCD) cohort study showed that every unit increase in TG was 
linearly associated with an increased risk of preeclampsia, pregnancy-induced 
hypertension, and preterm delivery. Total cholesterol was not associated with any 
of the outcome measures [53]. Women who have higher concentrations of small-
dense LDL fractions during pregnancy tend to have increased risk of cardiovascular 
disease later in life [53, 54].
In the multicenter, prospective Coronary Artery Risk Development in Young 
Adults study, 1010 women of which 49% identified as black with at least one single-
ton birth with 20 years of follow-up were evaluated. There was a U-shaped relation-
ship between prepregnancy cholesterol concentrations and preterm birth risk with 
both low ((<156 mg/dl) and high cholesterol (>195 mg/dl) related to preterm birth 
risk [55]. Observational and experimental evidence increasingly supports a relation 
between growth and development during fetal and infant life and health in later 
years. Additionally, preterm newborns have been found to be at an increased risk of 
CVD later in life [56].
3.5.2.1 Antihyperlipidemia therapy
Pregnant women are generally excluded from clinic trials, thus the data are 
limited. HMG-CoA reductase inhibitors have been associated with teratogenicity 
and congenital malformation and are not recommended. Fibrates and nicotinic acid 
have not been well studied and are not recommended. Omega fatty acids, on the 
other hand, can be safely used as monotherapy to decrease TG levels.
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4. Dyslipidemia in CKD and ESRD
4.1 Epidemiology and pathogenesis
Patients with CKD and ESRD are at an increased risk of CVD, and are more likely 
to die because of adverse cardiovascular events [57]. In addition to traditional risk fac-
tors like hypertension, diabetes mellitus, dyslipidemia, and a family history of CAD, 
patients with CKD are plagued by nontraditional risk factors like homocysteinemia, 
mineral bone disease, carbamylation, and chronic inflammation [58, 59]). As CKD 
progresses, an unstable vascular environment ensues which threatens endothelial 
function and lipoprotein integrity and thus potentiating adverse cardiovascular 
outcomes. Figure 1 shows mechanism of dyslipidemia in this population.
Dyslipidemia in these patients is undoubtedly one of the strongest risk factors 
for these adverse cardiovascular outcomes. Despite these data, however, CVD 
remains underdiagnosed and undertreated in patients with CKD. Dyslipidemia 
has been found to be distinctly different from the general population and variable 
depending on the stage of CKD [60]. The lipid profile of patients with nondialysis-
dependent CKD is usually composed of low HDL-C and high triglycerides with 
normal to low total cholesterol and low-density lipoprotein cholesterol [61]. In fact, 
plasma triglycerides start to increase in early stages of CKD and show the highest 
concentrations in nephrotic syndrome and in dialysis patients, especially those who 
are treated with peritoneal dialysis [60]. In patients with nondialysis-dependent 
CKD, the hypertriglyceridemia has been attributed to delayed catabolism and 
increased hepatic production of triglyceride-rich lipoproteins, and to a smaller 
extent by the presence of lipase inhibitors [62]. This altered catabolism in turn 
results in the accumulation of triglyceride-rich lipoproteins, like IDL and small-
dense LDL (sdLDL) which are highly atherogenic [63, 64].
Though elevated LDL-C is not a typical feature of these patients, sdLDL, an LDL 
subtype, is increased and carries the ability to penetrate the vessel wall, becomes 
oxidized, and triggers the atherosclerotic process. The subfractions of HDL in CKD 
and ESRD are also different than that of the general population. In uremia [65], LDL 
and HDL, their subfractions, lipidomes, and proteomes, gradually become more 
susceptible to structural modifications such as carbamylation, oxidation, glycation, 
nitration, and homocysteinylation [66, 67]. Most of these effectors are irreversible 
and amplify the uptake by the scavenger receptors on the surface of macrophages 
[60]. HDL’s vital components like ApoA-I, PON-1, and LCAT are altered, ultimately 
attenuating HDL’s cyto- and vascular-protective properties [68] . The reduced 
Figure 1. 
Mechanism of dyslipidemia in chronic kidney disease (CKD), end stage renal disease (ESRD), and human 
immunodeficiency virus (HIV) patients.
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PON-1 activity further predisposes LDL and HDL to more oxidation and, in turn, 
dysfunction and enhanced atherogenic potential [69]. In fact, it has been found that 
increasing serum HDL-C over time is paradoxically associated with significantly 
higher all-cause and cardiovascular mortality [70].
4.2 Management
Recent studies show that statin therapy can decrease cardiovascular mortal-
ity in CKD population. Heart Protection Study and Anglo-Scandinavian Cardiac 
Outcomes Trial (ASCOT) demonstrated that CKD patients treated with simvastatin 
exhibited a reduction of cardiovascular morbidity and mortality [71, 13]. Results 
from the Pravastatin Pooling Project showed similar cardioprotective effects [72]. 
Atorvastatin and rosuvastatin also reduced the relative risk of cardiovascular events 
in CKD patients and improved outcomes were found with higher atorvastatin doses 
[73–75]. Study of Heart and Renal Protection (SHARP) trial randomized 9270 
patients with CKD with no prior history of CAD and found that simvastatin 20 mg 
plus ezetimibe 10 mg daily safely reduced the incidence of major atherosclerotic 
events in CKD patients [76].
KDIGO panel provides recommendations for dyslipidemia in patients at 
all stages of CKD based on a few large, randomized controlled trials and post 
hoc analyses of the subgroup of CKD patients from statin trials in the general 
population [76, 77]. In adult CKD patients ≥50 years age, statin therapy alone 
is recommended for those with GFR ≥ 60 ml/min and statin or statin/ezetimibe 
therapy is recommended for GFR < 60 ml/min. In adults aged 18–49 years 
with CKD, statin treatment is recommended in patients with known coronary 
disease, diabetes mellitus, prior ischemic stroke or estimated 10-year incidence 
of coronary death or nonfatal myocardial infarction >10%. Neither ACC/
AHA nor KDIGO guidelines recommend initiation of statin therapy or com-
bination treatment with statin and ezetimibe in dialysis-dependent patients 
on the basis of results from the AURORA (A Study to Evaluate the Use of 
Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival 
and Cardiovascular Events) and Deutsche Diabetes Dialyse Studie (4-D) trials. 
However, patients already on lipid-lowering therapy at the time of progression 
to dialysis may continue treatment [76, 78–80].
Novel and innovative therapies are needed to address the multiple lipid/lipopro-
tein abnormalities that facilitate high cardiovascular risk and mortality in patients 
with dialysis-dependent CKD.
5. Dyslipidemia in renal transplant recipients
5.1 Epidemiology
Risk of cardiovascular events in kidney transplant recipients is markedly 
elevated as compared to people without CKD. Prevalence of hyperlipidemia ranges 
from 16 to 78% in kidney transplant recipients. Hypercholesterolemia has peak 
incidence at 12 months posttransplant and correlates with excessive body weight. 
After transplantation, increases in total cholesterol, LDL-C, very-low-density 
lipoprotein (VLDL)-cholesterol, and TG have been noted. In addition, LDL-C may 
be more susceptible to oxidation, making the particle more atherogenic. HDL-C 
levels may be normal or even high although the composition of HDL may not be 
normal [81].
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5.2 Mechanisms of dyslipidemia
Immunosuppressive agents contribute significantly to hyperlipidemia in renal 
transplant recipients. Corticosteroids induce insulin resistance. Hyperinsulinemia 
leads to increased hepatic uptake of free fatty acids (FFA) which constitute the main 
substrate for VLDL cholesterol synthesis. There is increased conversion of VLDL to 
LDL cholesterol, leading to a rise in LDL cholesterol levels and downregulation of 
LDL receptors [81–83]. Calcineurin inhibitors interfere with binding of LDL- 
to-LDL receptor leading to increase in LDL-C, interfere with bile acid synthesis and 
lead to LDL receptor downregulation. Cyclosporine is highly lipophilic. Tacrolimus 
is associated with less hyperlipidemia [84]. Rapamycin inhibits lipoprotein lipase, 
associated with decrease in apolipoprotein-B 100 catabolism, and increases secre-
tion of VLDL cholesterol [85]. Other secondary causes include nephrotic syndrome, 
hypothyroidism, diabetes mellitus, excessive alcohol intake, obesity, chronic liver 
disease, and genetic predisposition.
5.3 Management
Lipid profile evaluation including total cholesterol, LDL, HDL, and triglyceride 
levels is recommended. Kidney Disease Improving Global Outcomes (KDIGO) sug-
gest treatment with statins in adult kidney transplant recipients [77]. Assessment 
of Lescol in Renal Transplantation (ALERT) trial is the only multicenter, random-
ized, double-blind, placebo-controlled trial in renal transplant recipients. In this 
study, 2102 renal transplant recipients with total cholesterol 4·0–9 mmol/l were 
randomized to receive fluvastatin (n = 1050) or placebo (n = 1052). After a mean 
follow-up of 5 years, fluvastatin lowered LDL cholesterol concentrations by 32%. 
Although cardiac deaths and nonfatal myocardial infarction seemed to be reduced, 
fluvastatin did not reduce rates of coronary intervention procedures or mortality 
[86]. Of 1787 patients who completed ALERT, 1652 (92%) were followed in the 
extension trial with mean follow-up of 6.7 years which showed 29% reduction in 
cardiac death or definite nonfatal myocardial infarction in the fluvastatin arm [87]. 
Due to the known interaction of calcineurin inhibitors through CYP3A isoenzyme 
system, lower doses of statins are generally used as compared to general population. 
Among fibrates, fenofibrate is less myotoxic than gemfibrozil when combined with 
statin but fenofibrate should be avoided in advanced CKD. Bile acid sequesterants 
are not widely used due to gastrointestinal side effects and can also interfere with 
absorption of immunosuppressants. Ezetimibe is considered safe in renal transplant 
recipients.
6. Dyslipidemia in HIV
Antiretroviral therapy (ART) has prolonged the survival of HIV-infected individ-
uals, which, in effect, has increased the prevalence of comorbidities, like coronary 
heart disease. Studies have shown that HIV-infected individuals have higher cardio-
vascular disease (CVD) risk than uninfected persons in the United States [88–90]. 
Paisible et al. reported a 1.5–2-fold increased risk of incident myocardial infarction 
compared with uninfected subjects [91]. Among HIV patients, women have been 
found to have higher CVD risk than men [92]. Risk, however, cannot be attributed to 
HIV alone as traditional CVD risk factors like smoking [93], dyslipidemia, diabetes 
mellitus, and hypertension [92] have been found to be more common among those 
infected. Table 1 summarizes the traditional and nontraditional risk factors for 
cardiovascular disease in special populations.
11
Dyslipidemia in Special Populations, the Elderly, Women, HIV, Chronic Kidney Disease…
DOI: http://dx.doi.org/10.5772/intechopen.82831
Their lipid profile is comprised of hypertriglyceridemia, increased sdLDL, and 
low HDL-C levels [94, 95]. Atheromas have been found to have larger lipid pools 
with dystrophic calcifications [96]. Consequently, the coronary arteries have a 
higher burden of coronary plaque and prevalence of detectable calcium [97–99]. 
These plaques are rupture-prone and associated with inflammation [100] and 
monocyte activation [101]. As a result, patients tend to have higher rates of subclin-
ical vascular disease [102, 103]. ART-associated lipodystrophy has been linked with 
these cardiac and metabolic complications [104]. However, newer ART medications 
have had less effect on dyslipidemia and related myocardial events [105]. Still, CD4 
cell depletion and immune dysfunction perpetuates HIV-related atherosclerosis, 
irrespective of ART [106]. Silverberg et al. reported that CD4 counts <200 cells/mm3 
were significantly associated with increased risk of MI [105]. While viral load 
and prior ART use were not associated with MI, unsuppressed HIV viremia was 
associated with MI [89] and stroke [107]. Dyslipidemia and its effects on the 
cardiovascular system in HIV are dynamic and multimodal. In these states of 
chronic inflammation, it is difficult to associate quantities of cholesterol types with 
outcomes. That is, in these special populations, there may not be a “good” or “bad” 
cholesterol, but rather dysfunctional lipoprotein atherosclerosis.
Studies have shown that statins are safe and beneficial in those infected with 
HIV; however, the use of statins remains relatively low [89, 108, 109]. Reasons 
include (1) the low prevalence of elevated LDL-C, (2) their uncertain efficacy for 
CVD prevention, and (3) the potential to adverse side effects and negative drug-
drug interactions [80]. National Lipid Association (NLA) recommends that all 
HIV-infected patients be first assessed for cardiovascular risk and counseled about 
lifestyle interventions like diet, exercise, and smoking for the prevention of athero-
sclerotic cardiovascular disease. In addition, a fasting lipid panel should be obtained 
in all newly identified HIV-infected patients before and after starting antiretroviral 
therapy. TG >500 mg/dl that are refractory to lifestyle modification or changes in 
ART (if an option) should be treated with either a fibrate (fenofibrate preferred) 
or prescription omega-3 fatty acids to lower TG to <500 mg/dl. Non-HDL-C and 
Traditional Non-traditional
CKD HIV Renal transplant
Diabetes mellitus 
and insulin 
resistance
Hyperhomocysteinemia Antiretroviral 
therapy
Immunosuppressive 
therapy:
Glucocorticoids
Calcineurin inhibitor
Rapamycin
Hypertension Hypercalcemia and 
hyperphosphatemia
Dyslipidemia Chronic inflammation and 
oxidative stress
Obesity and 
physical inactivity
Anemia of chronic disease
Smoking Microalbuminuria
Family history of 
atherosclerosis
Nephrotic syndrome
Age
Gender
CKD, chronic kidney disease; HIV, human immunodeficiency virus.
Table 1. 
Traditional and nontraditional risk factors for cardiovascular disease in special populations.
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LDL-C should be reassessed for appropriate management with statin therapy with 
caution of drug-drug interactions and side effects. To this end, the NLA Expert 
Panel recommends clinicians to prescribe pitavastatin as the generally preferred 
agent in HIV-infected patients [80].
7. Racial differences in dyslipidemia
7.1 Epidemiology
National Health and Nutrition Examination Survey (NHANES) is the primary 
data source for national prevalence rates of dyslipidemia in the US with data on 
Whites, black/African Americans, and Hispanics/Latinos but is limited in data on 
Asian subgroups [110]. NHANES data in 2013 showed that the prevalence rate of 
high LDL-C was highest among Mexican men (40%) and women (30%), followed 
by non-Hispanic black men (33%) and women (31%). Non-Hispanic white men 
(30%) and women (29%) had the lowest prevalence of high LDL-C. The prevalence 
rates of low HDL were 20% in black men and 10% in black women as compared 
to prevalence rates among non-Hispanic white men (33%) and women (12%) and 
Hispanic American men (34%) and women (15%). NHANES data in 2008 reported 
prevalence of high TG in 35% of Hispanic Americans, 33% among non-Hispanic 
whites, and 16% among non-Hispanic blacks [111]. American Heart Association 
(AHA), in conjunction with the Centers for Disease Control and Prevention, and 
the National Institutes of Health reported prevalence of hyperlipidemia in non-
Hispanic black men (32.6%) and non-Hispanic black women (36.1%), Hispanic men 
(43.1%), Hispanic women (41.2%), non-Hispanic white men (37%) and in women 
(43.4%) and for non-Hispanic Asians, prevalence was 39.9% in men and 40.5% in 
women [112]. Data from outpatient cohort of adults 35 years or older from 2008 
to 2011 in northern California found that compared with non-Hispanic whites, 
every minority subgroup had an increased prevalence of high triglycerides except 
blacks. Most minority groups had an increased prevalence of low HDL-C, except for 
Japanese and blacks. The prevalence of HDL-C was increased among Asian Indians, 
Filipinos, Japanese, and Vietnamese compared with non-Hispanic whites [113]. 
Table 2 shows cholesterol levels in minority populations compared to non-Hispanic 
Whites in the United States.
The Study of Health Assessment and Risk in Ethnic groups (SHARE), a pro-
spective Canadian trial, showed that South Asians including Asian Indians had 
an increased prevalence of total cholesterol, high LDL-C, low HDL-C, and high 
TG compared to European and Chinese cohort [114]. The Multi-Ethnic Study of 
Atherosclerosis (MESA), a multicenter cohort study of 6814 adults aged 45 to 
84 years who were free of clinical CVD at baseline were evaluated for CVD risk 
and self-reported use of lipid-lowering therapy. Black and Hispanic Americans had 
prevalence of dyslipidemia that was comparable to that of non-Hispanic whites 
but were less likely to be treated and controlled. Ethnic disparities were attenuated 
substantially by adjustment for health-care access variables [115]. Data from the 
Hispanic Community Health Study (HCHS)/Study of Latinos (SOL), an observa-
tional study, showed high prevalence of dyslipidemia among Central American men 
and Puerto Rican women [116].
7.2 Dyslipidemia and cardiovascular outcomes
In the US, cardiovascular mortality rates are highest in blacks as compared to 
Hispanics [117]. An early study of CHD among Japanese migrants compared with 
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Japanese living in Japan showed higher rates of CAD in Japanese immigrants in 
America [118]. In a study of immigrant Asian Indian men in US, Enas et al. reported 
high prevalence of CAD, low HDL-C levels, and hypertriglyceridemia. Authors sug-
gested “insulin resistance” as a common pathogenetic mechanism [119]. Increased 
risk of CAD in south Asian community was seen in data from other studies as well 
[114, 120, 121].
The 2013 ACC-AHA guidelines for the treatment of cholesterol expand the 
indications for statin therapy for the prevention of CVD. Ten-year ASCVD risk 
assessment calculator has been added to determine statin use [122]. ASCVD risk 
calculator is derived from cohorts that included African-American or white partici-
pants with at least 12 years of follow-up. Data from other racial/ethnic groups were 
insufficient, precluding their inclusion in the final analyses. The equations were 
also assessed in external validation studies with data from other available cohorts 
[123]. For other ethnic groups, ACC/AHA recommends use of the equations for 
non-Hispanic whites, though it acknowledges that estimates may underestimate the 
risk for American Indians, some Asian Americans (e.g., of south Asian ancestry), 
and some Hispanics (e.g., Puerto Ricans), and may overestimate the risk for others, 
including some Asian Americans (e.g., of east Asian ancestry) and some Hispanics 
(e.g., Mexican Americans) [124].
7.3 Statin metabolism
There are several genetic variants associated with altered statin metabolism. Single-
nucleotide polymorphisms in the genes that encode the organic anion-transporting 
polypeptide (OATP) 1B1 (521 T > C), which regulates hepatic uptake of statins, and 
the adenosine triphosphate-binding cassette G2 (ABCG2) transporter (421C > A), 
which regulates hepatic efflux, have been reported [125–127]. Plasma exposure to 
rosuvastatin and its metabolites was significantly higher in Chinese, Malay, and Asian-
Indian subjects compared with white subjects living in Singapore [128]. Rosuvastatin, 
a HMG-CoA reductase inhibitor, is excreted into bile mediated by breast cancer 
resistance protein (BCRP). BCRP 421C > A polymorphism may play an important role 
in the pharmacokinetics of rosuvastatin in healthy Chinese males [129]. In a Japanese 
study, single-nucleotide polymorphisms in OATP-C, such as T521C (Val174Ala), has 
Percent of 
population
Total 
cholesterol
HDL LDL TGs Lp(a) ASCVD
Hispanics
 Men 17% ↑ ↓ ↑ ↑ ↔ ↑
 Women ↓
African Americans
 Men 13% ↔ ↑ ↓ ↓ ↑ ↑
 Women ↔ ↔
Asians (data limited) 6% ↑ ↓ ↑ ↑ – ↑
American Indians/
Alaska Natives (data 
limited)
2% – ↑ – – – ↑
HDL, high-density lipoprotein; LDL, low-density lipoprotein; Lp(a), lipoprotein (a), ASCVD, atherosclerotic 
cardiovascular disease.
Table 2. 
Cholesterol levels in minority populations compared to non-Hispanic Whites in the United States.
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been reported to be associated with altered pharmacokinetics of pravastatin [125]. 
In a US-based study cohort of 69 European-Americans and 38 African-Americans, 
SLCO1B1 genotype, in particular, the 521C allele, had a significant effect on the phar-
macokinetics of pravastatin. European-Americans demonstrated significantly higher 
pravastatin levels as compared to African-Americans [130]. There is less information 
on statin metabolism in other racial/ethnic minority groups. In a randomized placebo-
controlled trial of 25,673 patients, the absolute risk of myopathy with adding niacin-
laropiprant to statin-based LDL cholesterol-lowering therapy was more than 10 times 
as great among Chinese as compared to their European counterparts [131]. The relative 
risk of myopathy with niacin-laropiprant versus placebo was also higher in Chinese 
patients [132].
Lifestyle risk factors include unhealthy diet, obesity, and physical inactivity. 
Racial/ethnic disparities also exist in these lifestyle risk factors. According to the 
National Health Interview Survey (NHIS) 2008–2010, Asian adults were less likely 
to be current smokers or to be obese. Black adults were more likely to be physi-
cally inactive, to be obese, and to get insufficient sleep. Hispanics were less likely 
than non-Hispanic adults to smoke cigarettes, get insufficient sleep, but were 
more likely to be inactive in terms of aerobic and muscle-strengthening leisure 
time. Immigration and acculturation have a profound impact on lifestyle in both 
Hispanics and Asians in the US [133]. Asian Indian, Filipino, Vietnamese women, 
and Asian Indian men have increased risk dyslipidemias as compared to non-
Hispanic whites. Further research is needed to determine the role of dyslipidemia 
subtypes and other risk factors in explaining the higher risk of CVD in minority 
subgroups. By understanding these differences, clinicians will be able to provide 
more culturally competent recommendations on prevention and management of 
dyslipidemia.
8. Conclusion
In conclusion, differences in dyslipidemia patterns, risk factors, and manage-
ment exist in the elderly, women and pregnancy, CKD, ESRD, HIV, and different 
racial ethnic groups. Nevertheless, they are frequently underrepresented in clinical 
trials, which calls for more inclusive research that will develop stronger recommen-
dations of daily practice.
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